Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System

Chest - United States
doi 10.1016/j.chest.2015.11.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prs9 - Switching From Subcutaneous Treprostinil to Inhaled Treprostinil in Pulmonary Arterial Hypertension Treatment and Economic Impact Evaluation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Rapid Transition From Inhaled Iloprost to Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2013English

Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension From Intravenous Epoprostenol to Intravenous Treprostinil

American Journal of Cardiology
Cardiovascular MedicineCardiology
2007English

Tolerability and Clinical Efficacy of Inhaled Treprostinil in Patients With Group 1 Pulmonary Arterial Hypertension

Therapeutic Advances in Chronic Disease
Medicine
2018English

Long-Term Treprostinil in Pulmonary Arterial Hypertension: Is the Glass Half Full or Half Empty?

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2006English

Pulmonary Arterial Hypertension

Current Problems in Cardiology
MedicineCardiovascular MedicineCardiology
2011English

EXPRESS: Implantable System for Treprostinil: A Real-World Patient Experience Study

Pulmonary Circulation
PulmonaryRespiratory Medicine
2020English

Tissue Depth Study for a Fully Implantable, Remotely Powered and Programmable Wireless Neural Stimulator

International Journal of Nano Studies & Technology
2016English

Heritable Pulmonary Arterial Hypertension

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy